Potency and Safety of G12C Inhibitors in Solid Tumors: A Systematic Review

Background: The Kirsten rat sarcoma viral oncogene homolog (KRAS) gene, specifically the cysteine residue mutation KRAS (G12C), has garnered significant attention as a therapeutic target for solid cancer patients with KRAS mutations. Despite this interest, the efficacy and safety profiles of KRAS G1...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara El Zaitouni, Abdelilah Laraqui, Youssra Boustany, Soukaina Benmokhtar, Hicham El Annaz, Rachid Abi, Mohamed Rida Tagajdid, Safae El Kochri, El Arbi Bouaiti, Idriss Lahlou Amine, Rabii Ameziane El Hassani, Khalid Ennibi
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Clinical Medicine Insights: Oncology
Online Access:https://doi.org/10.1177/11795549251331759
Tags: Add Tag
No Tags, Be the first to tag this record!